Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer
Morten Ladekarl*, Louise Skau Rasmussen, Jakob Kirkegård, Inna Chen, Per Pfeiffer, Britta Weber, Halla Skuladottir, Kell Østerlind, Jim Stenfatt Larsen, Frank Viborg Mortensen, Henriette Engberg, Henrik Møller, Claus Wilki Fristrup
Dyk ned i forskningsemnerne om 'Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer'. Sammen danner de et unikt fingeraftryk.